Source: Zacks

Sierra: Sierra Oncology, Inc (SRRA) Upgraded to Buy: What Does It Mean for the Stock?

Sierra Oncology, Inc (SRRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Stephen Dilly's photo - President & CEO of Sierra

President & CEO

Stephen Dilly

CEO Approval Rating

90/100

Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more